GE Healthcare invests $37.5 million in Chinese bio-sciences manufacturing facility

GE Healthcare, which has U.S. headquarters in Waukesha, Wis., will invest $37.5 million to extend its production facility in Shanghai to meet increasing customer demand for its products in China and worldwide.

The GE Healthcare plant in Shanghai is currently undergoing a review process to be the first U.S .FDA approved site for contrast media in China, thus becoming able to supply product beyond China to the U.S. as well as numerous markets throughout the world.

Currently, the facility manufactures close to five million units of GE Healthcare's X-Ray and MRI products; Visipaque, Omnipaque and Omniscan, employing more than 400 people.

The investment will involve the expansion of the facility over the next two years to increase production capacity to 15 million units.

GE Healthcare has been active commercially in China since 1991 and today employs 3,000 people in more than 25 locations across the country with principle sites in Beijing, Shanghai, Wuxi and Guangzhou.